诺泰生物(688076) - 2025 Q4 - 年度业绩

Financial Performance - In 2025, the company achieved total operating revenue of CNY 1,942,799,144.82, representing a year-on-year increase of 19.57%[5] - The net profit attributable to the parent company was CNY 326,999,932.94, a decrease of 19.14% compared to the previous year[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 363,931,382.12, down 10.76% year-on-year[5] - The company's basic earnings per share decreased by 20.61% to CNY 1.04[5] - The weighted average return on net assets decreased by 5.65 percentage points to 11.28%[5] Assets and Equity - The company's total assets at the end of 2025 were CNY 6,733,330,456.35, an increase of 32.60% from the beginning of the year[5] - The equity attributable to the parent company increased by 11.86% to CNY 2,975,857,619.45 compared to the beginning of the year[5] - The company's share capital increased by 43.80% to CNY 316,051,897.00, primarily due to the conversion of capital reserves into share capital[12] Operational Challenges - The overall sales revenue growth was impacted by industry price fluctuations and increased fixed costs, leading to a decline in gross profit margin[10] - The company conducted impairment testing on certain assets, which affected the current period's performance[10]

Jiangsu Sinopep-Allsino Biopharmaceutical -诺泰生物(688076) - 2025 Q4 - 年度业绩 - Reportify